Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 496 entries
View as:

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Phase: N/A Priority: Normal
NCT ID: NCT01615068 Org: User:
Start: 06/05/12 End: 11/16/17 Due: 11/16/18

Patient Reported Symptoms in Ovarian Cancer (PRECISION)

Phase: N/A Priority: Normal
NCT ID: NCT01422265 Org: User:
Start: 06/30/11 End: 04/30/15 Due: 04/30/16

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

Phase: N/A Priority: Normal
NCT ID: NCT01277302 Org: User:
Start: 02/28/11 End: 10/31/12 Due: 10/31/13

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Phase: N/A Priority: Normal
NCT ID: NCT03361137 Org: User:
Start: 06/28/18 End: 03/13/20 Due: 03/13/21

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

Phase: N/A Priority: Normal
NCT ID: NCT06847854 Org: User:
Start: 12/08/22 End: 04/30/27 Due: 04/30/28

Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01335958 Org: User:
Start: 04/30/11 End: 02/28/14 Due: 02/28/15

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Phase: N/A Priority: Normal
NCT ID: NCT00095225 Org: User:
Start: 07/31/04 End: 11/30/06 Due: 11/30/07

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT01691898 Org: User:
Start: 09/27/12 End: 02/07/19 Due: 02/07/20

A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

Phase: N/A Priority: Normal
NCT ID: NCT01991210 Org: User:
Start: 02/06/14 End: 08/17/16 Due: 08/17/17

A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

Phase: N/A Priority: Normal
NCT ID: NCT01243892 Org: User:
Start: 11/30/10 End: 08/31/11 Due: 08/31/12

A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00299104 Org: User:
Start: 01/31/06 End: 07/31/13 Due: 07/31/14

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

Phase: N/A Priority: Normal
NCT ID: NCT06602453 Org: User:
Start: 01/17/25 End: 11/15/27 Due: 11/15/28

A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00977067 Org: User:
Start: 06/30/07 End: 11/30/09 Due: 11/30/10

A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00081614 Org: User:
Start: 03/31/04 End: 07/31/05 Due: 07/31/06

A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)

Phase: N/A Priority: Normal
NCT ID: NCT00314574 Org: User:
Start: 12/31/05 End: 11/30/09 Due: 11/30/10

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

Phase: N/A Priority: Normal
NCT ID: NCT00262067 Org: User:
Start: 12/31/05 End: 12/31/13 Due: 12/31/14

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)

Phase: N/A Priority: Normal
NCT ID: NCT01374425 Org: User:
Start: 08/31/11 End: 07/31/15 Due: 07/31/16

Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT00056823 Org: User:
Start: 03/31/03 End: 12/31/05 Due: 12/31/06

A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)

Phase: N/A Priority: Normal
NCT ID: NCT00403403 Org: User:
Start: 03/31/07 End: 06/30/09 Due: 06/30/10

A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00673920 Org: User:
Start: 04/24/08 End: 10/26/09 Due: 10/26/10

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase: N/A Priority: Normal
NCT ID: NCT05306340 Org: User:
Start: 08/03/22 End: 10/15/26 Due: 10/15/27

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Phase: N/A Priority: Normal
NCT ID: NCT00257608 Org: User:
Start: 01/31/06 End: 11/30/14 Due: 11/30/15

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

Phase: N/A Priority: Normal
NCT ID: NCT03693625 Org: User:
Start: 09/27/18 End: 10/23/19 Due: 10/23/20

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

Phase: N/A Priority: Normal
NCT ID: NCT04171765 Org: User:
Start: 09/30/20 End: 01/23/23 Due: 01/23/24

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Phase: N/A Priority: Normal
NCT ID: NCT02833350 Org: User:
Start: 09/09/16 End: 07/02/18 Due: 07/02/19